Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment

Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment

Abstract Background High morbidity and mortality rates of the COVID-19 pandemic have made it a global health priority. Acute respiratory distress syndrome (ARDS) is one of the most important causes of death in COVID-19 patients. Mesenchymal stem cells have been the subject of many clinical trials fo...

Full description

Bibliographic Details
Main Authors: Hamid Reza Aghayan, Fatemeh Salimian, Atefeh Abedini, Samrand Fattah Ghazi, Masud Yunesian, Sepideh Alavi-Moghadam, Jalil Makarem, Keivan Majidzadeh-A, Ali Hatamkhani, Maryam Moghri, Abbas Danesh, Mohammad Reza Haddad-Marandi, Hassan Sanati, Fereshteh Abbasvandi, Babak Arjmand, Pourya Azimi, Ardeshir Ghavamzadeh, Ramin Sarrami-Forooshani
Format: Article
Language:English
Published: BMC 2022-07-01
Series:Stem Cell Research & Therapy
Subjects:
Acute respiratory distress syndrome (ARDS)
Cell therapy
Coronavirus
COVID-19
Placenta mesenchymal stem cells (PL-MSC)
Online Access:https://doi.org/10.1186/s13287-022-02953-6

Internet

https://doi.org/10.1186/s13287-022-02953-6

Similar Items